Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 69

Results For "Meta"

755 News Found

Biosynthetic Technologies raises $7.5 million
News | February 08, 2022

Biosynthetic Technologies raises $7.5 million

Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.


Sun Pharma demonstrates strong performance on all fronts: ICICI Direct
News | February 04, 2022

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses


European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
Drug Approval | January 28, 2022

European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC

KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)


Agilent announces the Innovative Seahorse XF Pro Analyzer
Medical Device | January 25, 2022

Agilent announces the Innovative Seahorse XF Pro Analyzer

Optimized for pharma/biopharma to deliver a deeper understanding of cellular function


Green chemistry approaches to synthesis could make a big difference to pharma product outputs
News | January 20, 2022

Green chemistry approaches to synthesis could make a big difference to pharma product outputs

Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies


Abbisko Therapeutics enters global tie-up with Lilly to develop novel molecules
Biotech | January 18, 2022

Abbisko Therapeutics enters global tie-up with Lilly to develop novel molecules

The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise


Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease
Biotech | January 17, 2022

Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease

The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period


AIIMS now uses ImmersiveTouch for surgeries
Digitisation | January 14, 2022

AIIMS now uses ImmersiveTouch for surgeries

Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training


Wacker and Biosyntia to develop production process for sustainable biotin
Biotech | January 11, 2022

Wacker and Biosyntia to develop production process for sustainable biotin

The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative


Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
Biotech | January 11, 2022

Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer

First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC